Notably, the enhancement of NK cell anti-tumor efficacy by blockade of PD-1/PD-L1 is more important for the treatment of patients with tumors that are defective in MHC class I expression or display low mutational loads, because T cells are often inactive in these settings. Here, CD274 is linked to neoplasm.